Lentivirus-Mediated Expression of Mutant MGMT P140K Protects Human CD34 + Cells Against the Combined Toxicity of O 6 -Benzylguanine and 1,3-Bis(2-Chloroethyl)-Nitrosourea or Temozolomide
Authors:
- 1 August 2004
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 15 (8) , 758-769
Abstract
Lentiviral vectors are capable of efficiently transducing nondividing and slowly dividing cells, including hematopoietic stem cells, resulting in stable integration and sustained transgene expression. We constructed human immunodeficiency virus type 1-based self-inactivating lentiviral vectors to express either wild-type or an O6-benzylguanine (O6-beG)-resistant mutant form of the human O6-alkylguanine-DNA methyltransferase (MGMT; DNA-O6-methylguanine:[protein]-L-cysteine S-methyltransferase, EC 2.1.1.63) and transduced K562 and granulocyte colony-stimulating factor-mobilized human peripheral blood CD34+ cells. After transduction, K562 cells expressed high levels of MGMT as determined by Western blot, immunocytochemistry, and biochemical assay. A colony-forming survival assay showed significant protection against O6-beG plus 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) or temozolomide (TMZ) toxicity. Similarly, a single transduction of CD34+ cells resulted in a 13- to 14-fold increase in the level of MGMT expression. In comparison with non-transduced cells, mutant MGMTP140K-transduced CD34+ cells showed significant resistance against the combined toxicity of O6-beG with either TMZ or BCNU: there was an ~9-fold increase in the survival of colony-forming cells as indicated by the IC50 values after O6-beG plus TMZ treatment and an ~5-fold increase in the case of O6-beG plus BCNU treatment. These results show that lentivirus-mediated expression of MGMTP140K can efficiently protect the hematopoietic compartment against the combined toxicity of O6-beG plus TMZ or BCNU.Keywords
This publication has 39 references indexed in Scilit:
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Occurrence of leukaemia following gene therapy of X-linked SCIDNature Reviews Cancer, 2003
- Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction as a Method for Determining Lentiviral Vector Titers and Measuring Transgene ExpressionHuman Gene Therapy, 2003
- Temozolomide in combination with interferon α‐2b in patients with metastatic melanomaCancer, 2002
- Murine Leukemia Induced by Retroviral Gene MarkingScience, 2002
- Lentiviral Vectors for Enhanced Gene Expression in Human Hematopoietic CellsMolecular Therapy, 2000
- Efficient Gene Transfer to Human Peripheral Blood Monocyte-Derived Dendritic Cells Using Human Immunodeficiency Virus Type 1-Based Lentiviral VectorsHuman Gene Therapy, 2000
- Enhancing hemopoietic drug resistance: A rationale for reconsidering the clinical use of mitozolomideCancer Gene Therapy, 2000
- Human long-term culture initiating cells are sensitive to benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and protected after mutant (G156A) methylguanine methyltransferase gene transferCancer Gene Therapy, 1999
- Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferaseGene Therapy, 1998